---
title: A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
nct_id: NCT07241039
overall_status: RECRUITING
phase: PHASE1
sponsor: AbbVie
study_type: INTERVENTIONAL
primary_condition: Advanced Squamous Tumors
countries: United States, Israel, Japan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07241039.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07241039"
ct_last_update_post_date: 2026-02-17
last_seen_at: "2026-05-12T07:14:04.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

**Official Title:** A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination With Budigalimab (ABBV-181) in Adult Subjects With Advanced Squamous Tumors

**NCT ID:** [NCT07241039](https://clinicaltrials.gov/study/NCT07241039)

## Key Facts

- **Status:** RECRUITING
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 220
- **Lead Sponsor:** AbbVie
- **Conditions:** Advanced Squamous Tumors
- **Start Date:** 2025-11-20
- **Completion Date:** 2030-10
- **CT.gov Last Update:** 2026-02-17

## Brief Summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in combination with budigalimab (ABBV-181) in adults with advanced squamous tumors.

ABBV-711 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-711 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 220 adult participants will be enrolled in the study across 40 sites worldwide.

In part 1, oral ABBV-711 tablets will be given in escalating doses alone to participants with squamous (sq) tumors. In part 2 oral ABBV-711 tablets will be given at a selected dose from part 1 to participants with squamous non-small cell lung cancer (sqNSCLC), or head and neck squamous cell carcinoma (HNSCC). In part 3, oral ABBV-711 tablets will be given in escalating doses in combination with intravenously (IV) infused budigalimab to participants with sq tumors. In part 4 oral ABBV-711 tablets will be given at a selected dose from part 3 in combination with IV infused budigalimab to participants with sqNSCLC, or HNSCC. The estimated duration of the study is up to approximately 5 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent questionnaire, medical assessments, blood tests, and scans.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Must have progressed on or after standard of care therapy and have no curative therapy available (participants who have refused, are considered ineligible for or are intolerant to standard of care therapy are eligible).
* Received programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) targeted agents are eligible.
* Confirmation of available archival tumor tissue (formalin-fixed paraffin-embedded \[FFPE\] block or freshly cut slides) or provision of fresh tissue biopsy is required for enrollment in this study for gene expression assessment. If archival tissue requirements cannot be met then the AbbVie therapeutic area Medical Director or designee should be contacted to determine subject eligibility.
* For head and neck squamous cell carcinoma (HNSCC) participants enrolled in backfill (Part 1 and 3), subjects must provide consent to paired biopsies which are pretreatment and on treatment fresh tumor biopsies from the same tumor lesion, unless deemed not feasible by the investigator where upon consultation with the Sponsor is required. Paired biopsies are encouraged (when safe and feasible) but not required for subjects with squamous non-small cell lung cancer (sqNSCLC) enrolled in the backfill (Part 1 and 3).
* Evaluable and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Exclusion Criteria:

* Active autoimmune diseases besides vitiligo, type 1 diabetes, hypothyroidism, hypopituitarism and psoriasis (not requiring systemic treatment); history of primary immunodeficiency, bone marrow transplantation, or solid organ transplantation. Active inflammatory bowel disease unfit for trial in the opinion of the investigator, including subjects requiring systemic therapy with biologics or immunosuppressive therapy within the past 2 years.
* Treatment with any of the following:

  * Anti-cancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-711. Palliative radiation therapy for bone, skin or symptomatic metastases with 10 fractions or less is not subject to a washout period.
  * Radiation therapy for central nervous system metastases within 14 days prior to first dose.
* Subject has systemically used known moderate/strong inhibitors of cytochrome P450 3A (CYP)3A enzyme isoform subfamily within 14 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of study treatment.
* Has systemically used known moderate/strong inducers of CYP3A within 14 days prior to the first dose of study treatment.
* Requires treatment with known moderate or strong inhibitors or inducers of CYP3A from the first dose of study treatment and for the duration of the study.
* Administration or consumption of any of the following within 3 days prior to first dose of study treatment and while on study treatment: grapefruit or grapefruit products, Seville oranges (including marmaladecontaining Seville oranges), and star fruit.
* Current or prior use of immunosuppressive medication within 14 days prior to the first dose of the study treatment. The following are exceptions to this criterion:

  * Intranasal, inhaled, topical steroids or local steroid injections (e.g., intra-articular injection);
  * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication);
  * Systemic corticosteroids at doses not to exceed 10 mg/day of prednisone or equivalent.
```

## Arms

- **Part 1: ABBV-711 Monotherapy Dose Escalation** (EXPERIMENTAL) — Participants will receive ABBV-711 in escalating doses alone, as part of the 5 year study duration.
- **Part 2a: ABBV-711 Monotherapy Dose Expansion** (EXPERIMENTAL) — Participants will receive ABBV-711 dose A alone, as part of the 5 year study duration.
- **Part 2b: ABBV-711 Monotherapy Dose Expansion** (EXPERIMENTAL) — Participants will receive ABBV-711 dose B alone, as part of the 5 year study duration.
- **Part 3: ABBV-711 + BudigalimabDose Escalation** (EXPERIMENTAL) — Participants will receive ABBV-711 in escalating doses in combination with budigalimab, as part of the 5 year study duration.
- **Part 4a: ABBV-711 Budigalimab Dose Expansion** (EXPERIMENTAL) — Participants will receive ABBV-711 dose A in combination with budigalimab, as part of the 5 year study duration.
- **Part 4b: ABBV-711 Budigalimab Dose Expansion** (EXPERIMENTAL) — Participants will receive ABBV-711 dose B in combination with budigalimab, as part of the 5 year study duration.

## Interventions

- **ABBV-711** (DRUG) — Oral Tablet
- **Budigalimab** (DRUG) — Intravenous Infusion

## Primary Outcomes

- **Number of Participants with Adverse Events (AE)s** _(time frame: Up to Approximately 5 Years)_ — An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
- **Best overall Response (BOR)** _(time frame: Up to Approximately 5 Years)_ — BOR is defined as partial response (PR) or better per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

## Secondary Outcomes

- **Duration of BOR Response** _(time frame: Up to Approximately 5 Years)_
- **Clinical Benefit Rate (CBR)** _(time frame: Up to Approximately 5 Years)_
- **Progression-free survival (PFS)** _(time frame: Up to Approximately 5 Years)_
- **Duration of response (DOR)** _(time frame: Up to Approximately 5 Years)_
- **Overall survival (OS)** _(time frame: Up to Approximately 5 Years)_
- **Area Under the Concentration-Time Curve (AUC) of ABBV-711** _(time frame: Up to Approximately 5 Years)_
- **Maximum Observed Concentration (Cmax) of ABBV-711** _(time frame: Up to Approximately 5 Years)_
- **Time to Cmax (Tmax) of ABBV-711** _(time frame: Up to Approximately 5 Years)_
- **Half-Life (t1/2) of ABBV-711** _(time frame: Up to Approximately 5 Years)_

## Locations (9)

- City Of Hope Comprehensive Cancer Center /ID# 276550, Duarte, California, United States — _RECRUITING_
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432, Irvine, California, United States — _RECRUITING_
- START Midwest /ID# 272505, Grand Rapids, Michigan, United States — _RECRUITING_
- Carolina BioOncology Institute /ID# 272380, Huntersville, North Carolina, United States — _RECRUITING_
- Next Oncology - Irving /ID# 276659, Irving, Texas, United States — _RECRUITING_
- The Chaim Sheba Medical Center /ID# 276798, Ramat Gan, Tel Aviv, Israel — _RECRUITING_
- Rambam Health Care Campus- Haifa /ID# 276799, Haifa, Israel — _RECRUITING_
- Hadassah Medical Center-Hebrew University /ID# 276800, Jerusalem, Israel — _RECRUITING_
- Kansai Medical University Hospital /ID# 276586, Hirakata-shi, Osaka, Japan — _RECRUITING_

## Recent Field Changes (last 30 days)

- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.city of hope comprehensive cancer center /id# 276550|duarte|california|united states` — added _(2026-05-12)_
- `locations.city of hope - orange county lennar foundation cancer center /id# 278432|irvine|california|united states` — added _(2026-05-12)_
- `locations.start midwest /id# 272505|grand rapids|michigan|united states` — added _(2026-05-12)_
- `locations.carolina biooncology institute /id# 272380|huntersville|north carolina|united states` — added _(2026-05-12)_
- `locations.next oncology - irving /id# 276659|irving|texas|united states` — added _(2026-05-12)_
- `locations.the chaim sheba medical center /id# 276798|ramat gan|tel aviv|israel` — added _(2026-05-12)_
- `locations.rambam health care campus- haifa /id# 276799|haifa||israel` — added _(2026-05-12)_
- `locations.hadassah medical center-hebrew university /id# 276800|jerusalem||israel` — added _(2026-05-12)_
- `locations.kansai medical university hospital /id# 276586|hirakata-shi|osaka|japan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07241039.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07241039*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*